Clinical Trials Browser

Phase 2/3 × Biliary Tract Neoplasms × pembrolizumab × Clear all

NCT05429697 2022-09-27

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

Phase 2/3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma